Jupiter Asset Management Ltd. Raises Stock Position in Haemonetics Co. (NYSE:HAE)

Jupiter Asset Management Ltd. raised its stake in Haemonetics Co. (NYSE:HAEFree Report) by 12.3% during the third quarter, HoldingsChannel.com reports. The fund owned 11,624 shares of the medical instruments supplier’s stock after purchasing an additional 1,274 shares during the quarter. Jupiter Asset Management Ltd.’s holdings in Haemonetics were worth $1,041,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Capital Research Global Investors increased its holdings in Haemonetics by 0.5% in the 2nd quarter. Capital Research Global Investors now owns 6,689,539 shares of the medical instruments supplier’s stock valued at $569,547,000 after acquiring an additional 35,797 shares during the last quarter. Wellington Management Group LLP increased its holdings in Haemonetics by 21.5% in the 1st quarter. Wellington Management Group LLP now owns 6,165,363 shares of the medical instruments supplier’s stock valued at $389,776,000 after acquiring an additional 1,091,484 shares during the last quarter. Vanguard Group Inc. increased its holdings in Haemonetics by 3.4% in the 3rd quarter. Vanguard Group Inc. now owns 5,195,195 shares of the medical instruments supplier’s stock valued at $384,600,000 after acquiring an additional 173,113 shares during the last quarter. Schroder Investment Management Group increased its holdings in Haemonetics by 5.3% in the 2nd quarter. Schroder Investment Management Group now owns 996,208 shares of the medical instruments supplier’s stock valued at $84,817,000 after acquiring an additional 50,584 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Haemonetics by 5.1% in the 2nd quarter. Geode Capital Management LLC now owns 991,418 shares of the medical instruments supplier’s stock valued at $84,409,000 after acquiring an additional 47,696 shares during the last quarter. 99.38% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

HAE has been the topic of a number of research reports. Barrington Research reduced their price target on shares of Haemonetics from $114.00 to $105.00 and set an “outperform” rating on the stock in a report on Friday, November 3rd. StockNews.com downgraded shares of Haemonetics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 16th.

Read Our Latest Analysis on HAE

Haemonetics Stock Performance

Haemonetics stock opened at $74.20 on Monday. The company’s 50-day moving average price is $83.19 and its 200-day moving average price is $86.43. Haemonetics Co. has a twelve month low of $73.02 and a twelve month high of $95.26. The company has a quick ratio of 1.76, a current ratio of 2.92 and a debt-to-equity ratio of 0.91. The company has a market cap of $3.77 billion, a PE ratio of 30.16, a price-to-earnings-growth ratio of 1.89 and a beta of 0.34.

Haemonetics (NYSE:HAEGet Free Report) last posted its earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.94 by $0.10. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. The firm had revenue of $336.20 million for the quarter, compared to the consensus estimate of $320.84 million. During the same period in the previous year, the firm posted $0.85 EPS. The business’s quarterly revenue was up 10.1% on a year-over-year basis. On average, equities research analysts forecast that Haemonetics Co. will post 3.92 EPS for the current fiscal year.

Haemonetics Company Profile

(Free Report)

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.

Further Reading

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAEFree Report).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.